CERTARA

Changing the Game in Drug Development and Patient Access

At Certara, we are innovators, dedicated to helping our clients develop new therapies and target unmet medical needs, expand existing therapies to other subpopulations, communicate scientific information in the language of regulatory success and market access, balance risk-benefit profiles, differentiate therapies from the competitive landscape, and unlock millions of dollars in R&D savings.



Company Stats



800+ Employees including

280+

PhD, PharmD, & MD consultants



Certara software is used by major regulatory agencies and considered a "gold standard" by the US FDA



110+

Global submissions to regulators and health authorities in the last 3 years from

250+

Regulatory science consultants

90% —

of all novel drugs approved by the US FDA in the past 3 years were supported by Certara software or services

1,700

companies, academic institutions, global non-profits, and leading regulatory agencies in

60

countries partner with Certara

Impactful Science—From Bench to Market

Leveraging Model-informed Drug Development, Regulatory Science and Real World Value
Assessments to Optimize R&D and Commercial Decisions

M&S quantitative solutions enable a well pressure-tested development, regulatory, and patient access strategy


MIDD, market access, HEOR, and real-world evidence information must be presented, written and packaged through the most effective and compelling submissions

Integrating real-world value assessments with MIDD and regulatory strategy throughout the development cycle will optimize market value

A modern, state-of-the-art drug development strategy uses quantitative methods to demonstrate safety, efficacy, quality, and comparator effectiveness to regulators and payers

Certara's Capabilities





Science and Technology Decision-support Platform



Key decisions analyzed and informed by Certara's work include:

Making informed and quantitative **go/no go portfolio** decisions

Pressure testing and **optimizing** drug development and market access decisions

Selecting **first-in-human**, final dose, and dosing regimen

Comparing drug candidates for **safety**, **efficacy**, and **commercial viability**

Developing safer, targeted, and more efficient trial designs

Informing on comparative effectiveness and commercial potential

Determining optimal and alternative drug formulations

Identifying drug-drug interactions and other safety concerns

Optimizing product labeling

Analyze real world outcomes for drug value assessment

Facilitating **regulatory and health authority** communications

Determining and implementing the optimal regulatory filing strategy

